1. ALLA AKTIER
  2. NYHETER
  3. BONESUPPORT

Bonesupport

Nyheter Bonesupport Nyheter alla bolag

BONESUPPORT HOLDING AB (publ) – Publishes Q1 2023 interim report

MAR

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2023.

CONTINUED STRONG GROWTH

JANUARY – MARCH 2023

  • Net sales increased by 80 percent (66 percent at constant exchange rates) and amounted to SEK 119.7 million (66.3).
  • The North America (NA) segment reported a sales growth of 109 percent (87 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 34 percent (32 percent at constant exchange rates).
  • The gross margin amounted to 90.5 percent (90.5).
  • Operating result before effects from the Group’s incentive programs amounted to SEK +4.6 million (-12.5). Reported operating result amounted to SEK +0.8 million (-16.5).
  • Earnings per share, before and after dilution, were SEK +0.00 (-0.32).

"Strong sales growth driven by CERAMENT G in the US." Emil Billbäck, CEO


EVENTS DURING THE REPORTING PERIOD
The FDA has announced that the label extension application for CERAMENT G, to include open fracture/trauma, should be made within the 510(k) regulatory framework and not within the De Novo regulatory framework.

EVENTS AFTER THE REPORTING PERIOD
Nothing to report.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-27 08:00 CEST.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 329 million in 2022. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

Bonesupport Q1 2023 EN

Datum 2023-04-27, kl 08:00
Källa MFN
Bifogade filer
Bonesupport Q1 2023 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!